1 Asthma Stability Model for Inhaled Corticosteroid Dose-Response Wallace P. Adams, PhD OGD/OPS/CDER/US FDA Advisory Committee for Pharmaceutical Science.

Slides:

Advertisements

Similar presentations

Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

Advertisements

Topical Bioequivalence Update Robert Lionberger, Ph.D. Office of Generic Drugs.

CBER Isolagen Therapy (IT) BLA FDA Clinical Review Agnes Lim, MD Yao-Yao Zhu, MD, PhD DCEPT/OCTGT/CBER, FDA October 9, 2009 Advisory Committee Meeting.

Research Study Designs

Clinical bioequivalence. Specific example n A manufacturer wishes to change its approved production method for standardized fedweed pollen extract n CBER.

Difficulties in showing a dose- response with locally-acting nasal sprays and aerosols for allergic rhinitis Badrul A. Chowdhury, MD, PhD Medical Team.

NDAC December 14, Clinical Endpoints for Nasal Decongestants Xu Wang, M.D., Ph.D. Medical Officer Division of Pulmonary and Allergy Products Nonprescription.

Inhaled corticosteroids in preschool asthmatic children

PK and PD Studies for Systemic Exposure of Locally Acting Drugs Industry View Lester I. Harrison, PhD Division Scientist 3m Pharmaceuticals.

PHARMACODYNAMIC TESTING FOR ORALLY INHALED DRUGS: CORTICOSTEROIDS Staffan Edsbäcker, Assoc.Prof. University of Lund and Experimental Medicine, AstraZeneca,

High-Throughput Screening Speeding Up CF Drug Discovery >10,000 Primary assays/day High-throughput screening CFTR Modulator Drug SAR based Medicinal Chemistry.

FDA Nasal BA/BE Guidance Overview

Qian H. Li, Lawrence Yu, Donald Schuirmann, Stella Machado, Yi Tsong

Venkata Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

Difficulties in showing a dose- response with locally-acting nasal sprays and aerosols for allergic rhinitis Badrul A. Chowdhury, MD, PhD Medical Team.

DALLA CLINICA AL LABORATORIO: TRASLAZIONE INVERSA Milano 3 Febbraio 2009 SILVIO GARATTINI.

1 The June 1999 Draft BA/BE Guidance for Nasal Aerosols and Nasal Sprays: History, Recommendations and Local Delivery Issues Wallace P. Adams, Ph.D. OPS/CDER/FDA.

Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,

Antidepressants and Suicidality in Adults: Statistical Evaluation Mark Levenson, Ph.D.* and Chris Holland, M.S. Statistical Safety Reviewers Quantitative.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of.

Pulmonary and Allergy Drugs Advisory Committee Thursday, 17 January 2002 ADVAIR and FLOVENT DISKUS Supplements for the COPD indication: SUMMARY and QUESTIONS.

Pulmonary-Allergy Drugs Advisory Committee January 17, FLOVENT ® DISKUS ® NDA , S004 GlaxoSmithKline Pulmonary-Allergy Drugs Advisory Committee.

Challenges of Non-Inferiority Trial Designs R. Sridhara, Ph.D.

Asma na Infância Renato T. Stein, M.D. Pontifícia Universidade Católica Porto Alegre, Brazil.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pediatric Exclusivity 1-Year Adverse Event Reporting for Drug Products Containing.

FDA Advisory Committee May 15, 2003 Genentech Marketing Application STN / 0 Omalizumab Recombinant human anti-IgE for treatment of asthma Efficacy.

Strategies for asthma management VARIABLE ! Prof Huib Kerstjens Groningen Research Institute for Asthma and COPD University Medical Center Groningen.

1 QT Evaluation Studies: Pharmacometric Considerations Leslie Kenna, Peter Lee and Yaning Wang Office of Clinical Pharmacology and Biopharmaceutics CDER/FDA.

4/26/001 Clinical Studies for Local Delivery of Nasal Aerosols and Sprays Izabela J. Roman, MD, PhD Founder & Medical Director Target Research Associates,

The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.

1 ORALLY INHALED AND NASAL DRUG PRODUCTS FOR LOCAL ACTION Current FDA BA/BE Background and Issues Wallace P. Adams, Ph.D. OPS/CDER/FDA OINDP Subcommittee.

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.

Center for Professional Advancement Generic Drug Approvals Course Bioequivalence & Bioavailability Michael A. Swit, Esq. Vice President.

Food and Drug Administration Center for Drug Evaluation and Research Lessons Learned from Growth Studies with Orally Inhaled and Intranasal Corticosteroids.

Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview

August 20, 2003FDA Antiviral Drugs Advisory Committee Meeting 1 Statistical Considerations for Topical Microbicide Phase 2 and 3 Trial Designs: A Regulatory.

CLINICAL EFFICACY TESTING for NASAL DRUGS Mary M. Fanning, M.D., Ph.D. Associate Director for Medical Affairs Office of Generic Drugs, FDA June 4, 1999.

WHO Prequalification Programme June 2007 Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification.

1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.

1 Subcommittee Report: Orally Inhaled and Nasal Drug Products (OINDP) Wallace P. Adams, Ph.D. OPS/CDER/FDA Advisory Committee for Pharmaceutical Science.

Using Product Development Information to Address the Bioequivalence Challenges of Highly-variable Drugs Lawrence X. Yu, Ph. D. Director for Science Office.

Penn CTSI Research Seminar Clinical Trials November 10, 2015 Vernon M. Chinchilli, PhD Distinguished Professor and Chair Department of Public Health Sciences.

1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.

A Pharmacokinetic Drug Interaction Study of Drug-72 and Drug-12 Department of Mathematic & Statistics York University Yufeng Lin Xiaofeng Zhou.

Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.

Orally Inhaled and Nasal Drug Products Subcommittee Introduction and Objectives Eric B. Sheinin Deputy Director Office of Pharmaceutical Science Center.

Evaluation of a Scaling Approach for Highly Variable Drugs Sam H. Haidar, Ph.D., R.Ph. Office of Generic Drugs Advisory Committee for Pharmaceutical Sciences.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

Study Designs for Acute Otitis Media: What can each design tell us? C. George Rochester, Ph.D. Anti-Infective Advisory Committee Meeting, July 11, 2002.

CDER / FDA1 Clinical Study Options for locally acting nasal suspension products Robert J. Meyer, MD Director, Div. Of Pulmonary and Allergy Drug Products.

Tiotropium Bromide as an Adjunct Therapy to Inhaled Corticosteroids in the Treatment of Adults with Chronic Asthma Kevin Dennis Pacific University School.

LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,

Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.

Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.

Opiate Therapy in Chronic Cough Alyn H. Morice, Madhav S. Menon, Siobhan A. Mulrennan, Caroline F. Everett, Caroline Wright, Jennifer Jackson and Rachel.

1 Once-daily indacaterol versus twice-daily salmeterol for COPD ; a placebo-controlled comparison R2 정명화 Eur Respir J 2011; 37: 273–279.

Reference based multiple imputation;

Welcome Clinical Trials October 11, 2016 Vernon M. Chinchilli, PhD

Filming: 15th of Febuary 2016, London, UK

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy Robert A.

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma Kai-Michael Beeh, MD, Frank Kanniess, MD, Frank Wagner, MD, Cordula.

Stanley J. Szefler, MD, Richard J. Martin, MD

H.William Kelly, PharmD Journal of Allergy and Clinical Immunology

Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: A real-world observational study David Price, FRCGP,

The efficacy and safety of omalizumab in pediatric allergic asthma

Stanley J. Szefler, MD, Richard J

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Roflumilast in aggiunta ai corticosteroidi inalatori

Eugenio Andraca-Carrera

Presentation transcript:

1 Asthma Stability Model for Inhaled Corticosteroid Dose-Response Wallace P. Adams, PhD OGD/OPS/CDER/US FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology 23 July 2008

2 Outline of the Presentation Methods to establish BE Challenges to ICS BE Asthma stability model: Pilot study –crossover vs parallel design –estimates of sample size for a BE study Asthma stability model: FDA research Pharmacodyamic study data analysis

3 Methods for Establishment of BE In vivo studies in humans comparing drug or active metabolite in an accessible biologic fluid In vivo studies in humans comparing a pharmacodynamic endpoint Comparative clinical trials to demonstrate BE Comparative in vitro studies 21 CFR (b)

4 DOSE-RESPONSE Reduced efficacy Reduced safety Response Equivalence Adapted from JN Pritchard, ANZSRS Annual Meeting, Brisbane, Mar 2001

5 Inhaled Corticosteroids (ICS) Dose-response * –Differences from placebo for each active dose are statistically significant –A dose-response generally exists shallow –Lack of statistical significance in response between adjacent doses high variability of response –4-fold or greater dose differences generally required to detect statistical significance Carryover between treatment periods is a concern for crossover study designs –Unequal carryover can bias the estimate of difference between treatment means *PJ Barnes et al, AJRCCM 1998;157:S1-53

6 Subjects age >18 yrs with asthma 50-75% of predicted N=50-59 per treatment WW Busse et al, JACI 1999;104: Dose-Response (D-R): CFC vs HFA Beclomethasone Dipropionate Treatments BDP for 6 weeks Parallel group design Up to 28 day ICS washout with placebo MDI 100, 400 or 800 mcg daily (BID dosing), blinded to dose

7 Dose-Response (D-R): CFC-BDP and HFA-BDP WW Busse et al, JACI 1999;104:

8 WW Busse et al, JACI 1999;104: , cited in JA Vanden Burgt et al, JACI 2000;106: Relative Potency of CFC-BDP and HFA-BDP (Finney Bioassay Method)

9 Asthma Stability after Oral Prednisone Model Pilot study in 12 adult asthmatics Randomized two period crossover study Oral prednisone (40 mg BID) wash-in, 4-7 days Two doses of HFA-BDP; 100, 800 mcg/day 21 day treatment period with ICS Periodic measurement of pulmonary function Repeat wash-in (4-7 day), crossover ICS (21 day) RC Ahrens et al, AJRCCM, 2001;164:

10 Sample Size Estimates (based on the Ahrens Pilot Study) Assume –2 by 2 study design (2 doses of each preparation) –Finney bioassay –90% confidence interval –BE interval on the dose scale is % –power = 80% –parallel or crossover study design Sample size estimates –based on ‘s’ and ‘b’ at end of treatment period –‘s’ is SD for responses from ANOVA –‘b’ is dose-response slope –low s/b ratio increases study power RC Ahrens et al, AJRCCM, 2001;164:

11 Mean AM FEV1 Responses/b ratios RC Ahrens et al, AJRCCM, 2001;164: Mean Responses by Study Treatment Day

12 RC Ahrens et al, AJRCCM, 2001;164: Study Design: Parallel vs Crossover

13 Asthma Stability Model: FDA Study Objectives Oral prednisone versus high dose ICS –Effect on maximum FEV1 value during high dose run-in of each crossover treatment –Effect on observed D-R Characterize D-R based on three treatment levels Study efficiency of screening process for identifying subjects demonstrating sufficient D-R (study enrichment) Examine D-R of primary and secondary outcome variables Characterize D-R using linear, nonlinear and Emax modeling

14 Design and Conduct of the FDA Study Subjects –Persistent asthma, non-smoking –Exhibit dose-response during run-in Run-In Study Periods –14 day high-dose ICS run-in (220 mcg x 4 actuations BID) –28 day low-dose ICS run-in (44 mcg x 1 actuation BID) Study Treatment Periods –high dose corticosteroid burst oral prednisone on two periods, or ICS randomly assigned –4 randomized crossover periods double-blind, double-dummy 28 days per period 44 mcg (1 actuation), 88 mcg (2 actuations), 88 mcg, and 352 (8 actuations) mcg BID

15 Design and Conduct of the Study HDCB 7 day prednisone or 14 day FP Home spirometry: AM FEV 1 and PM FEV 1 every day Office spirometry at each clinical visit eNO at each clinic visit N = 30N = up to 120 (est.) Pre-study 7 day28 day Low dose run-in High dose run-in 14 day FP treatment 28 day N = 24 44, 88, 88, 352 mcg BID

16 BE Criteria on the Dose Scale: Theory W Gillespie, ACPS Meeting, 16 Aug 1996

17 Dose Scale Approach to Estimate Relative BA Drug X (hypothetical example) Revised from W Gillespie, ACPS Meeting, 16 Aug 1996 RLD MDI Dose (mcg) for RLD 2 (180 mcg) puffs of RLD RLD Dose of RLD that would result in a

18 Acknowledgments Project Advisory Group –Badrul Chowdhury, MD, PhD, Division of Pulmonary and Allergy Products, OND –Sally Seymour, MD, DPAD –Robert Lionberger, PhD, OGD/OPS –Bing Li, PhD, OGD/OPS –Wallace Adams, PhD, OGD/OPS Lawrence Yu, PhD, OGD/OPS